Trandolapril in Cushing's disease: Short-term trandolapril treatment in patients with Cushing's disease and essential hypertension

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 20, Issue 5, 1998, Pages 433-438

  Zacharieva, S ^a   Torbova, S ^b   Orbetzova, M ^a   Vergilova, J ^a   Nachev, E ^a   Wippermann, M ^c   Baurenski, L ^b   Angelova Gateva, P ^a   Tzingilev, D ^d  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b Cardiovasc Cent   (Bulgaria)

^c Nichols Institute Diagnostics   (Netherlands)

^d National Oncology Center Bulgaria   (Bulgaria)

Author keywords

Active renin; Cushing's disease; Kallikrein; Trandolapril

Indexed keywords

TRANDOLAPRIL;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CUSHING DISEASE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; KALLIKREIN URINE LEVEL; MALE; PATHOGENESIS; PLASMA RENIN ACTIVITY;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CUSHING SYNDROME; FEMALE; HUMANS; HYPERTENSION; INDOLES; KALLIKREINS; MALE; MIDDLE AGED; RENIN;

EID: 0031859755     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.1998.20.5.485705     Document Type: Article

References (35)

1. Christy, N.P., Laragh, J.H. Pathogenesis of hypokalemic alkalosis in Cushing's syndrome. New Engl J Med 1961, 265: 1083-8.
2. Schambelan, M.. Slaton, Jr., P.E., Biglieri, E.G. Mineralocorticoid production in hyperadrenocorticism. Am J Med 1971, 51: 299-303.
3. Arteaga, E., Biglieri, E.G., Kater, C.E., Lupez, J.M., Schambelan, M. Aldosterone-producing adrenocortical carcinoma. Ann Intern Med 1984, 101: 3316-21.
4. Zacharieva, S., Stoeva, I., Matrozov, P., Andonova, K. Plasma aldosterone response to metoclopramide in patients with Cushing's disease. Exp Clin Endocrinol 1993, 101: 138-43.
5. Krakoff, L., Nicolis, G., Anesel, B. Pathogenesis of hypertension in Cushing's syndrome. Am J Med 1975, 58: 216-20.
6. Krakoff, L.R., Eligovich, F. Cushing's syndrome and exogenous glucocorticoid hypertension. Clin Endocrinol Metab 1981, 10: 479-88.
7. Ulick, S., Wang, J.Z., Blumenfeld, J.D., Pickering, T.G. Cortisol inactivation overload: A mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1992, 74: 963-7.
8. Saruta, T., Suzuki, H., Handa, M., Igarashi, I., Kondo, K., Senba. S. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metabol 1986, 62: 275-9.
9. Hecker, M., Pörsti, I., Bara, A.T., Busse, R. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: Interaction at the receptor level. Br J Pharmacol 1994, 111: 238-44.
10. Wiseman, L.R., McTavish. D. Trandolapril: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in essential hypertension. Drugs 1994, 48(1): 71-90.
11. Arner, P., Wade, A., Engfeldt. P. et al. Pharmacokinetics and pharmacodynamics of irandolapril after repeated administration of 2 mg to young and elderly patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1994, 23(Suppl. 4): S44-9.
12. Amundsen, E., Putter. J., Friberger, P., Knos, M., Larsbraten, M., Claesen, P. Method for determination of glandular kallikrein by means of a chromogenic tripeptide substrate. Adv Exp Med Biol 1979, 120A: 83-95.
13. Orbetzova, M., Zacharieva, S., Anglova-Gateva, P., Muchá. I., Andonova, K. Effects of indomethacin and meclofenamate on kallikrein activity and a stable metabolite of prostaglandin E2 in healthy subjects. Endocrin Metab 1995, 2: 33-7.
14. Bricaire, H., Thibonnier, M., Hautecouverture, M., Corvol, P., Luton, J.P. Variations du système rénine angiotensine aldostérone dans la maladie de dishing. Nouv Presse Med 1980, 9: 1007-9.
15. Ritchie, C.M., Sheridan, B., Fraser, R., Hadden, D.R., Kennedy, A.L., Riddell, J., Atkinson, A.B. Studies on the pathogenesis of hypertension in Cashing's disease and acromegaly. Q J Med 1990, 76: 855-67.
16. Vetter, W., Vetter, H., Beckershoff, R., Redlich, B., Cottier, P., Siegenthaler, W. The effect of saralasin (1-sar-8-ala-angiotensin 11) on blood pressure in patients with Cushing's syndrome. Klin Wochenschr 1976, 54: 661-3.
17. Yasuda, G., Shionoiri, H., Umemura, S., Takasaki, I., Ishii. M. Exaggerated blood pressure response to angiotensin II in patients with Cushing's syndrome due to adrenocortical adenoma. Eur J Endocrinol 1994, 131: 582-8.
18. Hermus, A., Hobma, S., Pieters, G., Van de Calseyde, J., Smals, A., Kloppenborg, P. Are the hypokalemia and hypertension in Cushing's disease caused by apparent mineralocorticoid excess? Horm Metab Res 1991, 23: 572-3.
19. Greminger, P., Vetter, W., Groth, H., Luscher, T., Tenschert, W., Siegenthaler, W., Vetter, H. Captopril in Cushing's syndrome. Klin Wochenschr 1984, 62: 855-8.
20. Nakahashi, J., Shimamoto, K., Ura. N. et al. Comprehensive studies on the renal kallikrein-kinin system in essential hypertension. In: Kinin IV, Part B. Greenbaum, L.M., Margolius, H.S. (Eds.). Adv Exp Med Biol 1986, 198 B: 351-7.
21. Madeddu, P., Chao, J., Chao, L. et al. Urinary levels of kallikrein and kallistatin in pregnancy-induced hypertension. Hypertension in Pregnancy 1995, 14: 201-12.
22. Bönner, G., Autenrieth, R., Marin-Grez, M., Stocker, M., Berecek, K., Gross, F. Changes in urinary kallikrein activity in steroid induced hypertension. In: Serono Symposium N 50, "Endocrinology of Hypertension", Mantero, F., Biglieri, E.G., Edwards, C.K.W. (Eds.). Academic Press: London 1982. 307-13.
23. Siragy, H.M., Ibrahim, M.M., Jaffa, A.A., Mayfield, R., Margolius, H.S. Rat renal interstitial bradykinin, prostaglandin E2 and cyclic 3',5'-monophosphate: Effects of altered sodium intake. Hypertension 1994, 23: 1068-70.
24. Gardes, J., Baussant, T., Corvol, P., Menard, J., Alhenc-Gelas, F. Effect of bradykinin and kininogens in isolated rat kidney vasoconstricted by angiotensin II. Am J Physiol 1990, 258: F1273-81.
25. Geller, R.G., Margolius, H.S., Pisano, J.J., Keiser, H.R. Effects of mineralocorticoids , altered sodium intake and adrenalectomy on urinary kallikrein in rats. Circ Res 1979, 31: 857-61.
26. Marceau, F., Gendreau, M., Barabe, J., St-Pierre, S., Regoli, D. The degradation of bradykinin (BK) and of des-Arg 9 - BK in plasma. Can J Physiol Pharmacol 1981, 59: 131-8.
27. Campbell, D.J., Kladis, A., Duncan, A.M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994, 23: 439-49.
28. Imura, O., Shimamoto, K. Role of kallikrein-kinin system in the hypotensive mechanisms of converting enzyme inhibitors in essential hypertension. J Cardiovasc Pharmacol 1989, 13(Suppl. 3): S63-6.
29. Scicli, A.G., Carretero, O.A. Renal kallikrein-kinin system. Kidney Int 1986, 29: 120-30.
30. Zacharieva, S., Torbova, S., Orbetzova, M., Borisova, A-M., Andonova, K., Sheitanova, S. Effects of perindopril treatment on plasma and urine kallikrein activity and the stable metabolite of prostaglandin E2 in patients with essential hypertension. Meth Find Exp Clin Pharmacol 1996, 18(3): 205-9.
31. Quilley, J., Duchin, K.L., Hudes, E.M., McGiff, J.C. The antihypertensive effect of captopril in essential hypertension: Relationship to prostaglandins and the kallikrein-kinin system. J Hypertens 1987, 5: 121-8.
32. Verma, P.S., Gagnon, J.A., Miller, R.L. Intrarenal kallikrein-kinin activity in acute renovascular hypertension in dogs. Renal Physiol 1987, 10: 311-7.
33. Nishiyama, K., Igari, T., Nanba, S., Ishii, M. Long-term effects of delapril on renal function and urinary excretion of kallikrein, prostaglandin E2 and thromboxane B2 in hypertensive patients. Am J Hypertens 1991, 4(1 Pt 2): S52-3.
34. Misumi, J., Alhenc-Gelas, F., Marre, M., Marchetti, J., Corvol, P., Menard, J. Regulation of kallikrein and renin release by the isolated perfused rat kidney. Kidney Int 1983, 24: 58-65.
35. Jover, B., Hérizi, A., Mimran, A. Chronic kinin blockade and effect of ramipril in renal adaptation to sodium restriction. Hypertension 1996, 27: 79-84.